Carbidopa and levodopa levodopa 10 mg/mL and carbidopa 2.5 mg/mL oral suspension
Ingredients
| Ingredient | Role | For 100 mL |
|---|---|---|
| Levodopa | active | 1 g |
| Carbidopa | active | 250 mg |
| SyrSpend SF PH4 (liquid) | vehicle | q.s. to 100 mL |
- Strength
- levodopa 10 mg/mL and carbidopa 2.5 mg/mL
- Starting material
- Bulk powders (API)
- Container
- See the study
Amounts are ClinDose's arithmetic from the study's concentration; follow the study for the method.
Storage and beyond-use date
| Storage | BUD | Basis |
|---|---|---|
| Refrigerated | 90 days | Cited stability study. Duration supported by the cited stability study for this formula, container, and storage. |
| Room temperature | 90 days | Cited stability study. Duration supported by the cited stability study for this formula, container, and storage. |
Only the storage conditions the source covers are listed. Use the BUD assistant for other cases. The BUD may not be later than any component's expiration date. Verify against the current official USP chapter.
Ingredient checks
No FDA compounding list or NIOSH flags for the active ingredient.
Source
Mansourian M, Dijkers E, Silva CCV, Polonini HC. Compatibility of Commonly Used Active Pharmaceutical Ingredients in a Ready-to-Use Oral Suspending Vehicle. Pharmaceutics. 2023;15(10):2388. PMID 37896148. PMC10609746. License: CC BY (checked 2026-11-06). Read the article · DOI
For licensed clinicians. Use with clinical judgment.